$12.38 0.9 7.7%
Last Trade - 22/01/21
| Market Cap | ÂŁ844.4m |
| Enterprise Value | ÂŁ758.1m |
| Revenue | ÂŁ114.7m |
| Position in Universe | 2577th / 6630 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.21 | 13.9 | 20.6 | 38.0 | 89.1 | 101.2 | 139.6 | 160.9 | +142.3% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | November 4, 2003 |
| Public Since | June 14, 2017 |
| No. of Shareholders: | 115 |
| No. of Employees: | 574 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 93,339,242 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1001 Main St Ste 600, BUFFALO, 14203-1009, United States |
| Web | https://www.athenex.com/ |
| Phone | +1 716 8988625 |
| Contact | Tim McCarthy (IR Contact Officer) |
| Auditors | Deloitte & Touche LLP |
As of 22/01/21, shares in Athenex Inc are trading at $12.38, giving the company a market capitalisation of ÂŁ844.4m. This share price information is delayed by 15 minutes.
Shares in Athenex Inc are currently trading at $12.38 and the price has moved by -17.52% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Athenex Inc price has moved by -29.46% over the past year.
Of the analysts with advisory recommendations for Athenex Inc, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Athenex Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Athenex Inc is scheduled to issue upcoming financial results on the following dates:
Athenex Inc does not currently pay a dividend.
Athenex Inc does not currently pay a dividend.
Athenex Inc does not currently pay a dividend.
To buy shares in Athenex Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Athenex Inc are currently trading at $12.38, giving the company a market capitalisation of ÂŁ844.4m.
Here are the trading details for Athenex Inc:
Based on an overall assessment of its quality, value and momentum, Athenex Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Athenex Inc are currently priced at $12.38. At that level they are trading at 0.121% discount to the analyst consensus target price of 0.00.
Analysts covering Athenex Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.588 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Athenex Inc. Over the past six months, the relative strength of its shares against the market has been -8.3%. At the current price of $12.38, shares in Athenex Inc are trading at 5.67% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Athenex Inc.
Athenex Inc's management team is headed by:
Here are the top five shareholders of Athenex Inc based on the size of their shareholding:
